The gut microbiome in intravenous immunoglobulin-treated chronic inflammatory demyelinating polyneuropathyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers examined the gut microbiome of patients with chronic inflammatory demyelinating polyneuropathy (CIDP), an autoimmune disorder of peripheral nerves, and whether intravenous immunoglobulin (IVIg) treatment altered it.
How was it studied?
Stool samples from 16 CIDP patients were collected before and one week after IVIg infusion and compared to samples from 15 age-matched healthy subjects, using bacterial 16S rRNA gene sequencing.
What did they find?
CIDP patients had higher alpha-diversity (p = 0.005) and enrichment of Firmicutes including Blautia, Eubacterium hallii, and Ruminococcus torques, plus Actinobacteriota, versus healthy subjects. IVIg did not change microbiome composition over one week (p = 0.95).
Why it matters
CIDP shows a distinct gut microbial signature enriched in short-chain fatty acid producing Firmicutes, but this small pilot study cannot yet establish whether IVIg has any longer-term effect on the gut microbiome.